SJS Investment Consulting’s Greenwich LifeSciences GLSI Stock Holding History

SJS Investment Consulting’s Portfolio GLSI Stock Details GLSI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$127	Sell	7 -4	-36%	-$67	﹤0.01%	3021
2026 Q2	$259	Buy	+11	New	+$268	﹤0.01%	2427

Other funds holding GLSI

Newbridge Financial Services Group Boca Raton, Florida $868M AUM 42.47% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

Washington Trust Advisors Wellesley, Massachusetts $1.4B AUM 26.88% 1-Year Est. Return

North Star Investment Management Chicago, Illinois $1.85B AUM 21.53% 1-Year Est. Return

Root Financial Partners Encinitas, California $2.98B AUM 13.9% 1-Year Est. Return

SJS Investment Consulting's GLSI Position: Q3 2026 in Review

SJS Investment Consulting reduced its Greenwich LifeSciences (GLSI) stake by 36% in Q3 2026, selling an estimated $67 and leaving 7 shares worth $127. The position accounts for ﹤0.01% of the portfolio, ranked #3021.

SJS Investment Consulting first reported a position in GLSI in Q2 2026 and has held it in 2 quarters since. The position peaked at $259 in Q2 2026. 8 funds tracked by Wall St. Rank hold GLSI as of Q3 2026.

SJS Investment Consulting held 7 shares of Greenwich LifeSciences worth $127 as of Q3 2026.
SJS Investment Consulting sold 4 Greenwich LifeSciences shares in Q3 2026, an estimated $67.
Greenwich LifeSciences made up ﹤0.01% of SJS Investment Consulting's portfolio in Q3 2026, its #3021 holding.
SJS Investment Consulting first reported a position in Greenwich LifeSciences in Q2 2026 and has held it in 2 quarters since.
SJS Investment Consulting's Greenwich LifeSciences position peaked at $259 in Q2 2026.
8 funds tracked by Wall St. Rank held Greenwich LifeSciences as of Q3 2026.

Based on SJS Investment Consulting's 13F filing for Q3 2026, filed 26 Oct 2026.